Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

BACKGROUND: Hepatitis B virus (HBV) core protein-targeting antivirals (CpTAs) are promising therapeutic agents for treating chronic hepatitis B (CHB). In this study, the antiviral activity, pharmacokinetics (PK), and tolerability of ZM-H1505R (Canocapavir), a chemically unique HBV CpTA, were evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Haiyan, Mai, Jiajia, Wu, Min, Chen, Hong, Li, Xiaojiao, Li, Cuiyun, Liu, Jingrui, Liu, Chengjiao, Hu, Yue, Zhu, Xiaoxue, Jiang, Xiuhong, Hua, Bo, Xia, Tian, Liu, Gang, Deng, Aiyun, Liang, Bo, Guo, Ruoling, Lu, Hui, Wang, Zhe, Chen, Huanming, Zhang, Zhijun, Zhang, Hong, Niu, Junqi, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022191/
https://www.ncbi.nlm.nih.gov/pubmed/36927420
http://dx.doi.org/10.1186/s12916-023-02814-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022191/
https://www.ncbi.nlm.nih.gov/pubmed/36927420
http://dx.doi.org/10.1186/s12916-023-02814-w

Ejemplares similares